MRMoein Rajaei

Moein Rajaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Moein Rajaei has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Age reshapes selection on melanoma driver mutations

    by Yihan Liu, Jeffrey D. Mandell, Moein Rajaei, Douglas Brash, Jorge Alfaro-Murillo, Jeffrey P. Townsend

    Aging is a major risk factor for melanoma. However, it is unclear whether aging fuels tumor evolution by altering mutation rates, changing the microenvironmentally induced selection on drivers, or both. We analyzed 5472 melanomas, estimating how selection on individual variants changes with patient age while accounting for differing neutral mutation rates. Neutral mutation rates increased only modestly with age; ultraviolet damage remained predominant, but endogenous processes increasingly contributed to older tumors. In contrast, selection on major drivers was strongly age dependent: The advantage of BRAF V600E declined precipitously with age, whereas NRAS Q61 mutations gained advantage. TERT promoter mutations became more frequent, yet less advantageous. Aging therefore reshapes melanoma evolution primarily by altering selection, motivating age-conscious evaluation of clinical biomarkers and therapies.

  • Evolution of the rate, molecular spectrum, and fitness effects of mutation under minimal selection in Caenorhabditis elegans

    by Sayran Saber, Md Monjurul Islam Rifat, Fahimeh Rahimi, Michael Snyder, Amber Singh, Benjamin Eickwort, Yell Newhall, Moein Rajaei, Ayush Shekhar Saxena, Robyn E Tanny, et al.

    The rate, molecular spectrum, and fitness effects of mutations vary at all levels of the biological hierarchy, from within individual genomes to among taxonomic domains. Understanding the evolutionary factors underpinning that variation is of fundamental importance to biology. Accurate quantification of the properties of mutations requires that other evolutionary forces, especially natural selection, be minimized as much as possible. To investigate the evolution of the mutational process in C. elegans, we propagated a set of 100 “first order” mutation accumulation (O1MA) lines under minimal selection for ∼150 generations, divided each O1MA line into two “second order” MA (O2MA) lines and propagated them for another ∼150 generations, at which time the genome of each O2MA line was sequenced, and a subset of 50 O1MA families was assayed for competitive fitness. Over the course of the experiment, the mean nucleotide substitution mutation rate did not change, but the variance increased. In contrast, the indel mutation rate increased significantly. The two types of mutations fulfill the predictions of different theoretical models for the evolution of mutation rate. These results reinforce previous findings that the rate of indels is more sensitive to endogenous stress than the rate of nucleotide substitutions. Several evolutionary quandaries could be resolved if deleterious mutations interact synergistically (negative epistasis). Evidence for synergistic epistasis is famously inconclusive, although there is reason to think it may be more detectable under competitive conditions. However, a model of constant mutational effects on competitive fitness explains the results significantly better than a model including epistasis.

  • Open Access

    Deconvolving mutation and selection reveals stage-specific drivers of thyroid cancer

    by Moein Rajaei, Andrew Ju, Adebowale J. Adeniran, Jeffrey P. Townsend

    Objective: Mutational profiles of primary and metastatic thyroid cancer (THCA) have been examined by comparison of somatic mutation prevalences in the two stages, using P values to identify significant differences. However, prevalences and P values for mutations do not directly quantify the cancer effects of somatic variants. Methods: We calculated cancer effect sizes accounting for substantial gene- and site-specific mutation rates, to quantify somatic selection across stages. This approach provides a direct measure of cancer-driving impact of new mutations and reveals the genes that drive tumorigenesis and progression, and whether mutations have greater effects in primary or metastatic THCA. Results: Trinucleotide mutation profiles were similar between primary and metastatic THCA. Most canonical driver genes ( BRAF, NRAS, TP53, ATM, EIF1AX, KMT2C, NF1, RBM10, ARID1A, PIK3CA , and NKX2-1 ) exhibited stronger selection during initial tumorigenesis (from organogenesis to primary THCA) than during progression (from primary to metastatic THCA). Notably, TERT mutations have been shown to be at higher prevalence in metastatic tumors, yet their strongest selection occurred earlier, during tumor initiation. In contrast, RET mutations exhibited the opposite trajectory, experiencing weaker selection during tumorigenesis but stronger selection during metastatic progression. Conclusion: Cancer effect size analysis revealed dynamic shifts in selective pressures across THCA evolution, distinguishing genes that drive initiation from those that promote metastatic progression. This evolutionary framework provides a quantitative basis for understanding THCA pathogenesis and provides guidance for stage-specific precision-medicine therapeutic strategies.

  • Open Access

    Somatic evolution of prostate cancer: mutation, selection, and epistasis across disease stages

    by Moein Rajaei, Alexander Yang, Kira A. Glasmacher, Christopher N. Cross, Nic Fisk, Elizabeth B. Perry, Jeffrey D. Mandell, Stephen G. Gaffney, Takafumi N. Yamaguchi, Julie Livingstone, et al.

    Background: Somatic mutations involved in prostate cancer tumorigenesis and disease progression have been identified, but their evolutionary dynamics—including differential selective pressures across oncogenesis and metastatic spread—remain poorly understood. No prior study has systematically quantified the adaptive landscape from prostate organogenesis through tumor initiation and progression to metastatic castrate-resistant prostate cancer (mCRPC), nor characterized the selective epistatic interactions that structure this evolutionary trajectory. Methods and Findings: To address this gap, we analyzed 2,704 low- and high-risk primary tumors and metastatic castration-resistant prostate cancers to quantify the mutation rates, mutational processes, and scaled selection coefficients of somatic mutations across disease stages. Trinucleotide mutational patterns were stable, but both mutation load and mutation rates increased with progression. In parallel, selective pressures on specific somatic mutations changed substantially, revealing a dynamic adaptive landscape. Stage-specific selective effects were associated with significant synergistic and antagonistic selective epistasis among key driver genes. Early selection on SPOP mutations in the BRD3 binding domain were under strong positive selection, and they increased selection for subsequent RHOA mutations while decreasing selection for TP53 mutations. Antagonistic selective epistasis was evident between mutations of CUL3 and both SPOP and PIK3CA . Mutations in KMT2C increased the selection for mutations in TP53 , consistent with their frequent co-occurrence. Synergistic epistatic interactions between mutations of PTEN and both PIK3CA and AR support a strong therapeutic rationale for combined inhibition of PI3K/AR pathway in PTEN-deficient prostate cancers. Conclusions: These findings provide a comprehensive map of the evolving selective and epistatic forces that shape prostate cancer progression across clinical stages. By distinguishing shifts in selection from changes in mutation rate and revealing the extents of cooperative and conflicting relationships among driver mutations, our work identifies critical points of vulnerability and informs that design of therapeutic strategies that anticipate and intercept the somatic evolutionary trajectory of prostate cancer.

  • Open Access

    Evolution of the rate, molecular spectrum, and fitness effects of mutation under minimal selection in Caenorhabditis elegans

    by Sayran Saber, Md. Monjurul Islam Rifat, Fahimeh Rahimi, Michael Snyder, Amber Singh, Benjamin Eickwort, Yell Newhall, Moein Rajaei, Ayush Shekhar Saxena, Robyn E. Tanny, et al.

    The rate, molecular spectrum, and fitness effects of mutations vary at all levels of the biological hierarchy, from within individual genomes to among taxonomic domains. Understanding the evolutionary factors underpinning that variation is of fundamental importance to biology. Accurate quantification of the properties of mutations requires that other evolutionary forces, especially natural selection, be minimized as much as possible. To investigate the evolution of the mutational process in C. elegans , we propagated a set of 100 “first order” mutation accumulation (O1MA) lines under minimal selection for ∼150 generations, divided each O1MA line into two “second order” MA (O2MA) lines and propagated them for another ∼150 generations, at which time the genome of each O2MA line was sequenced, and a subset of 50 O1MA families was assayed for competitive fitness. Over the course of the experiment, the mean nucleotide substitution mutation rate did not change, but the variance increased. In contrast, the indel mutation rate increased significantly. The two types of mutations fulfill the predictions of different theoretical models for the evolution of mutation rate. These results reinforce previous findings that the rate of indels is more sensitive to endogenous stress than the rate of nucleotide substitutions. Several evolutionary quandaries could be resolved if deleterious mutations interact synergistically (negative epistasis). Evidence for synergistic epistasis is famously inconclusive, although there is reason to think it may be more detectable under competitive conditions. However, a model of constant mutational effects on competitive fitness explains the results significantly better than a model including epistasis.


  • Open Access

    Tracing the evolution of single-cell 3D genomes in Kras-driven cancers

    by Miao Liu, Shengyan Jin, Sherry S. Agabiti, Tyler B. Jensen, Tianqi Yang, Jonathan S. D. Radda, Christian F. Ruiz, Gabriel Baldissera, Moein Rajaei, Fang-Yong Li, et al.

    Although three-dimensional (3D) genome structures are altered in cancer, it remains unclear how these changes evolve and diversify during cancer progression. Leveraging genome-wide chromatin tracing to visualize 3D genome folding directly in tissues, we generated 3D genome cancer atlases of oncogenic Kras-driven mouse lung adenocarcinoma (LUAD) and pancreatic ductal adenocarcinoma. Here we define nonmonotonic, stage-specific alterations in 3D genome compaction, heterogeneity and compartmentalization as cancers progress from normal to preinvasive and ultimately to invasive tumors, discovering a potential structural bottleneck in early tumor progression. Remarkably, 3D genome architectures distinguish morphologic cancer states in single cells, despite considerable cell-to-cell heterogeneity. Analyses of genome compartmentalization changes not only showed that compartment-associated genes are more homogeneously regulated but also elucidated prognostic and dependency genes in LUAD, as well as an unexpected role for Rnf2 in 3D genome regulation. Our results highlight the power of single-cell 3D genome mapping to identify diagnostic, prognostic and therapeutic biomarkers in cancer.